Deerfield Management Company, L.P. (Series C) X4 Pharmaceuticals, Inc Transaction History

Deerfield Management Company, L.P. (Series C)

  • $5.38 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2020

May 15, 2020
SELL
$6.03 - $11.01 $2.71 Million - $4.95 Million
-449,437 Closed
0 $0
Q4 2019

Feb 14, 2020
SELL
$9.93 - $14.33 $1.14 Million - $1.64 Million
-114,304 Reduced 20.28%
449,437 $4.81 Million
Q3 2019

Nov 14, 2019
SELL
$11.06 - $15.75 $13,924 - $19,829
-1,259 Reduced 0.22%
563,741 $7.17 Million
Q2 2019

Aug 14, 2019
BUY
$12.57 - $21.67 $7.1 Million - $12.2 Million
565,000 New
565,000 $8.48 Million

Others Institutions Holding XFOR

# of Institutions
103
Shares Held
99.9M
Call Options Held
213K
Put Options Held
50.6K
View Full List

About X4 Pharmaceuticals, Inc

XFOR Quotes by TradingView
  • Ticker XFOR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,646,096
  • Market Cap $55.6M
  • Description
  • X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...
More about XFOR
Track This Portfolio

Track Deerfield Management Company, L.P. (Series C) Portfolio

Follow Deerfield Management Company, L.P. (Series C) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email